Minnesota's CVRx is starting up a post-market hypertension registry in Europe to keep tabs on patients who received its hypertension-treating Barostim Neo device. The company expects to enroll about 500 patients, and it will monitor safety data on the CE-marked device, currently available Germany, Italy, the Netherlands, Switzerland and Austria. And while the company made no mention of it, it's safe to assume CVRx is gathering the extra safety data to file for approval in other countries and expand its market share in the en-vogue sector of hypertension techs. Release